As part of the U.S. cancer moonshot, the Patent and Trademark Office is implementing a one-year pilot program Wednesday to provide for earlier review of patent applications pertaining to cancer immunotherapy. To qualify for the 12-month review, applications must claim a method of treating a cancer using immunotherapy, and the applicant must file a grantable "petition to make special" before June 29, 2017.